BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 12020064)

  • 1. Fulvestrant (AstraZeneca).
    Johnston SR
    Curr Opin Investig Drugs; 2002 Feb; 3(2):305-12. PubMed ID: 12020064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valdecoxib (Pharmacia).
    Gotta AW
    Curr Opin Investig Drugs; 2002 Feb; 3(2):240-5. PubMed ID: 12020053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ximelagatran (AstraZeneca).
    Hopfner R
    Curr Opin Investig Drugs; 2002 Feb; 3(2):246-51. PubMed ID: 12020054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deramciclane (Egis).
    Kõks S; Vasar E
    Curr Opin Investig Drugs; 2002 Feb; 3(2):289-94. PubMed ID: 12020062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fulvestrant ('Faslodex'): current and future role in breast cancer management.
    Howell A
    Crit Rev Oncol Hematol; 2006 Mar; 57(3):265-73. PubMed ID: 16473018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical development of fulvestrant ("Faslodex").
    Howell A; Abram P
    Cancer Treat Rev; 2005; 31 Suppl 2():S3-9. PubMed ID: 16198055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exubera. Inhale therapeutic systems.
    Bindra S; Cefalu WT
    Curr Opin Investig Drugs; 2002 May; 3(5):758-62. PubMed ID: 12090549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fulvestrant antiestrogen for treatment of breast cancer.
    Hancock CM
    Clin J Oncol Nurs; 2003; 7(2):201-2. PubMed ID: 12696217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The future of fulvestrant ("Faslodex").
    Howell A
    Cancer Treat Rev; 2005; 31 Suppl 2():S26-33. PubMed ID: 16198056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials.
    Vergote I; Robertson JF
    Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S11-4. PubMed ID: 15094759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tomoxetine (Eli Lilly & Co).
    Preti A
    Curr Opin Investig Drugs; 2002 Feb; 3(2):272-7. PubMed ID: 12020059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dalbavancin (Biosearch Italia/Versicor).
    Steiert M; Schmitz FJ
    Curr Opin Investig Drugs; 2002 Feb; 3(2):229-33. PubMed ID: 12020051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
    Mlineritsch B; Psenak O; Mayer P; Moik M; Namberger K; Hauser-Kronberger C; Greil R
    Breast Cancer Res Treat; 2007 Nov; 106(1):105-12. PubMed ID: 17295045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
    Robertson JF; Osborne CK; Howell A; Jones SE; Mauriac L; Ellis M; Kleeberg UR; Come SE; Vergote I; Gertler S; Buzdar A; Webster A; Morris C
    Cancer; 2003 Jul; 98(2):229-38. PubMed ID: 12872340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cariporide Aventis.
    Chin B; Lip GY
    Curr Opin Investig Drugs; 2000 Nov; 1(3):340-6. PubMed ID: 11249717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fulvestrant (Faslodex): current status in the therapy of breast cancer.
    Bundred N; Howell A
    Expert Rev Anticancer Ther; 2002 Apr; 2(2):151-60. PubMed ID: 12113237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ZD-1839 (AstraZeneca).
    Norman P
    Curr Opin Investig Drugs; 2001 Mar; 2(3):428-34. PubMed ID: 11575718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fulvestrant ("Faslodex"): clinical experience from the Compassionate Use Programme.
    Steger GG; Gips M; Simon SD; Lluch A; Vinholes J; Kaufman B; Wardley A; Mauriac L
    Cancer Treat Rev; 2005; 31 Suppl 2():S10-6. PubMed ID: 16198057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fulvestrant in the treatment of postmenopausal women with advanced breast cancer.
    Gradishar W
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):445-53. PubMed ID: 16001952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case studies of fulvestrant ("Faslodex") in postmenopausal women with advanced breast cancer.
    Abram P; Maass N; Rea D; Simon SD; Steger GG
    Cancer Treat Rev; 2005; 31 Suppl 2():S17-25. PubMed ID: 16199128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.